Genentech Halts Phase 3 Trials Testing Crenezumab for Early Alzheimer’s Disease
News
Two Phase 3 trials — CREAD 1 and CREAD 2 — evaluating crenezumab as a therapy for early Alzheimer’s disease have been discontinued, Genentech announced. The decision was based on ... Read more